Association of ITGA2 dual site variants with recurrent ischemic events in patients undergoing stenting for symptomatic intracranial atherosclerotic stenosis

doi:10.3969/j.issn.1006-7795.2026.03.002

Abstract

Abstract: Objective To investigate the correlation between gene polymorphisms and the occurrence of adverse clinical events following dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic stenosis. Methods A total of 195 patients were enrolled and categorized into 32 cases (those with clinical adverse events) and 163 controls (without events). Genotyping of 20 single nucleotide polymorphism (SNP) from 17 genes was executed. To address the imbalance in sample size between cases (n=32) and controls (n=163), weighted Logistic regression analysis was performed using frequency weights based on the reciprocal of group proportions. Weights were calculated to account for the unequal case-control ratio and improve the stability and reliability of regression estimates. Results The ITGA2 rs1126643 (C807T) and rs1062535 (G873A) polymorphisms were significantly correlated with adverse clinical events. Specifically, the mutant frequency of allele C (ITGA2 rs1126643) and allele G (ITGA2 rs1062535) was significantly higher in cases compared to controls (OR=2.97, 95%CI: 1.702-5.172, P=0.000 1; OR=3.27, 95%CI:1.762-6.066, P=0.000 2, respectively). Other genotypes showed no significant differences between the groups. Conclusion The ITGA2 C807T and G873A polymorphisms are associated with an increased risk of recurrent ischemic events in Chinese patients with symptomatic intracranial atherosclerotic stenosis after stenting. Detection of these variants may help identify individuals at high risk of recurrent ischemic events in this specific population.

Key words: intracranial atherosclerotic stenosis, ischemic events, dual antiplatelet therapy, single nucleotide polymorphism, genetic markers, ITGA2

CLC Number:

R743

Dong Yiwen, Ye Jiadan, Cheng Sheng, Yang Hongge, Li Ze, Di Xuan, Lou Xin, Li Xingang, Ma Ning. Association of ITGA2 dual site variants with recurrent ischemic events in patients undergoing stenting for symptomatic intracranial atherosclerotic stenosis[J]. Journal of Capital Medical University, doi: 10.3969/j.issn.1006-7795.2026.03.002.

References

［1］GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019［J］. Lancet Neurol, 2021, 20(10): 795-820.
［2］Ma Q F, Li R, Wang L J, et al. Temporal trend and attributable risk factors of stroke burden in China, 1990-2019: an analysis for the Global Burden of Disease Study 2019［J］. Lancet Public Health, 2021, 6(12): e897-e906.
［3］Bergmark B A, Mathenge N, Merlini P A, et al. Acute coronary syndromes［J］. Lancet, 2022, 399(10332): 1347-1358.
［4］Xian Y, Xu H L, Matsouaka R, et al. Analysis of prescriptions for dual antiplatelet therapy after acute ischemic stroke［J］. JAMA Netw Open, 2022, 5(7): e2224157.
［5］Simonte G, Guglielmini G, Falcinelli E, et al. High-on-treatment platelet reactivity predicts adverse outcome after carotid artery stenting: a prospective study［J］. Thromb Res, 2023, 222: 117-123.
［6］Shah J, Liu S M, Yu W G. Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines［J］. Stroke Vasc Neurol, 2022, 7(5): 406-414.
［7］Khan H, Kanny O, Syed M H, et al. Aspirin resistance in vascular disease: a review highlighting the critical need for improved point-of-care testing and personalized therapy［J］. Int J Mol Sci, 2022, 23(19):11317.
［8］Patel S, Arya V, Saraf A, et al. Aspirin and clopidogrel resistance in Indian patients with ischemic stroke and its associations with gene polymorphisms: a pilot study［J］. Ann Indian Acad Neurol, 2019, 22(2): 147-152.
［9］Ross S, Krebs K, Pare G, et al. Pharmacogenomics in stroke and cardiovascular disease: state of the art［J］. Stroke, 2023, 54(1): 270-278.
［10］Montinari M R, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots-a concise summary［J］. Vascul Pharmacol, 2019, 113: 1-8.
［11］Li X Q, Ma N, Li X G, et al. Association of PON1, P2Y12 and COX1 with recurrent ischemic events in patients with extracranial or intracranial stenting［J］. PLoS One, 2016, 11(2): e0148891.
［12］Zhao Z G, Li X G, Sun S S, et al. Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis［J］. Eur J Clin Pharmacol, 2016, 72(10): 1195-1204.
［13］Pereira N L, Rihal C S, So D, et al. Clopidogrel pharmacogenetics［J］. Circ Cardiovasc Interv, 2019, 12(4): e007811.
［14］Saiz-Rodríguez M, Belmonte C, Caniego J L, et al. Influence of CYP450 enzymes, CES1, PON1, ABCB1, and P2RY12 polymorphisms on clopidogrel response in patients subjected to a percutaneous neurointervention［J］. Clin Ther, 2019, 41(6): 1199-1212.e2.
［15］Pan Y S, Elm J J, Li H, et al. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of clopidogrel in high-risk patients with acute non-disabling cerebrovascular events (CHANCE) and platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trials［J］. JAMA Neurol, 2019, 76(12): 1466-1473.
［16］Brown T, Gonzales N. Optimizing choice of dual antiplatelet therapy in CYP2C19 loss-of-function carriers［J］. Neurology, 2023, 100(5): 223-224.
［17］Yip V L M, Pirmohamed M. Expanding role of pharmacogenomics in the management of cardiovascular disorders［J］. Am J Cardiovasc Drugs, 2013, 13(3): 151-162.
［18］Jackson S P. Arterial thrombosis-insidious, unpredictable and deadly［J］. Nat Med, 2011, 17(11): 1423-1436.
［19］Kunicki T J, Orchekowski R, Annis D, et al. Variability of integrin alpha 2 beta 1 activity on human platelets［J］. Blood, 1993, 82(9): 2693-2703.［20］Deckmyn H, Chew S L, Vermylen J. Lack of platelet response to collagen associated with an autoantibody against glycoprotein IA: a novel cause of acquired qualitative platelet dysfunction［J］. Thromb Haemost, 1990, 64: 74-79.
［21］Huang X Y, Fu W J, Mei Z Z, et al. Association between platelet glycoprotein Ia C807T gene polymorphism and ischemic stroke: a meta-analysis in a separate ethnic group［J］. Cell Mol Biol, 2017, 63(11): 111-115.
［22］Liu H, Wang Y, Zheng J, et al. Platelet glycoprotein gene Ia C807T, HPA-3, and Ibα VNTR polymorphisms are associated with increased ischemic stroke risk: evidence from a comprehensive meta-analysis［J］. Int J Stroke, 2017, 12(1): 46-70.
［23］De Oliveira M H, André C, Spector N, et al. 807C/T polymorphism in the platelet glycoprotein Ia gene in young patients with ischemic stroke of undetermined etiology［J］. Blood Coagul Fibrinolysis, 2007, 18(7): 599-602.
［24］Nikolopoulos G K, Tsantes A E, Bagos P G, et al. Integrin, alpha 2 gene C807T polymorphism and risk of ischemic stroke: a meta-analysis［J］. Thromb Res, 2007, 119(4): 501-510.
［25］Dodson P M, Haynes J, Starczynski J, et al. The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion［J］. Eye, 2003, 17(6): 772-777.
［26］Wu G L, Xi Y J, Yao L, et al. Genetic polymorphism of ITGA2 C807T can increase the risk of ischemic stroke［J］. Int J Neurosci, 2014, 124(11): 841-851.
［27］Lloyd-Jones D, Adams R J, Brown T M, et al. Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association［J］. Circulation, 2010, 121(7): 948-954.
［28］Lewis J P, Ryan K, O'Connell J R, et al. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes［J］. Circ Cardiovasc Genet, 2013, 6(2): 184-192.